Search the Newsreel

What Carter's (CRI)'s Strong Q2 Rebound And Completed Buybacks Means For Shareholders

Carter's, Inc. reported strong Q2 2026 results with sales of US$615.49 million and net income of US$104.96 million, alongside the completion of a US$97.57 million share repurchase program. Management projects approximately US$750 million in Q3 net sales and 2% to 3% full-year sales growth …

Why CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline Updates - And What's Next

CRISPR Therapeutics (CRSP) saw its stock rise by 11.6% following its second-quarter 2026 results, which included an increase in revenue to US$10.18 million, a narrowed net loss, and the expansion of CASGEVY's FDA approval to younger children. The company also announced new in vivo …

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

CRISPR Therapeutics AG (NASDAQ:CRSP) reported strong second-quarter revenues of US$10m, significantly beating estimates, and a smaller-than-expected statutory loss. Following these results, analysts have substantially increased revenue forecasts for 2026 to US$54.4m and reduced expected losses, anticipating significant growth. Despite these upgrades, the consensus price …

Cricut, Inc. (CRCT) CEO sells 180,000 shares under Rule 10b5-1 plan

Cricut, Inc. CEO Ashish Arora sold a total of 180,000 shares of Class A Common Stock between August 3 and August 5, 2026. These sales were conducted under a Rule 10b5-1 trading plan established on August 20, 2025, with weighted average prices ranging from …

Cricut CEO Ashish Arora sells USD 1.1 million of Class A common shares

Cricut CEO Ashish Arora sold 179,000 Class A common shares between August 3-5, totaling approximately $1.1 million. The sales prices ranged from $4.77 to $6.26 per share, and following these transactions, Arora now holds 4,207,105 shares in the company. This news brief was generated …

Cricut CEO Ashish Arora sells $938k in shares

Cricut CEO Ashish Arora recently sold 180,000 shares of Class A Common Stock worth approximately $938,672, executed under a Rule 10b5-1 trading plan. These sales occurred over three days in early August 2026, coinciding with a significant rally in CRCT shares. Despite the insider …

Criteo SA (CRTO) (Q2 2026) Earnings Call Highlights: AI-Driven Growth Offsets Enterprise ...

Criteo SA's Q2 2026 earnings revealed a mixed performance with strong AI-driven growth initiatives, particularly through the OpenAI partnership and Criteo GO, but these were offset by reduced spending from large enterprise Performance Media clients, leading to a downward revision of full-year guidance. The …

Bernstein downgrades Criteo stock rating on profit warning concerns

Bernstein downgraded Criteo S.A. (NASDAQ:CRTO) to Market Perform from Outperform, cutting its price target due to a profit warning and unexpected CFO change. Criteo shares experienced a significant decline, trading near their 52-week low despite the company surpassing Q2 2026 earnings expectations. Investor uncertainty …

Form 4 Cricut Inc For: 6 August By Investing.com

This article from Investing.com reports on a Form 4 filing for Cricut Inc (CRCT) dated August 6. Form 4s are SEC filings that disclose changes in ownership of company stock by insiders. The article indicates a slight positive movement in Cricut Inc's stock at …

Brazilian Critical Minerals (ASX:BCM) Rallies After Ema Study Defines the Development Case

Criteo (CRTO) Stock Sinks As Lower 2026 Outlook Resets Confidence

Criteo's stock (CRTO) fell 24% after the company lowered its 2026 outlook, despite solid Q2 revenue and adjusted EBITDA. The market reacted to the guidance cut as a sign of reduced long-term earnings power, rather than just a temporary client-specific issue. While bulls point …

Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?

Criteo S.A. Q2 2026: Revenue $428M, Net income $11.8M — 10-Q Summary

Criteo S.A. (CRTO) reported a Q2 2026 revenue of $428 million, an 11% year-over-year decrease from $482.7 million in Q2 2025. Net income also fell significantly to $11.8 million from $22.9 million in the prior year. The company attributed the revenue decline to softness …

CRITEO APPOINTS CONNOR MCGOGNEY AS CHIEF FINANCIAL OFFICER

Criteo S.A. (NASDAQ: CRTO) has announced the appointment of Connor McGogney as its new Chief Financial Officer, effective August 10, 2026. McGogney, currently the Chief Strategy Officer, will also continue to oversee strategy, corporate development, and partnerships. He succeeds Sarah Glickman, who served as …

Strata Critical Medical Reports Q2 2026 Results: Full Earnings Call Transcript

Strata Critical Medical reported strong Q2 2026 results with significant sequential growth in clinical revenue and increased clinical gross margins, driven by strategic acquisitions. The company raised its 2026 revenue and adjusted EBITDA guidance, reflecting accelerated clinical growth and M&A, despite short-term logistics margin …

Free cash flow of Scribe Therapeutics Inc. – NASDAQ:SCTX

This article provides a brief mention of the free cash flow for Scribe Therapeutics Inc. (NASDAQ: SCTX) as found on TradingView. It appears to be a financial data point without further analysis or details within the snippet provided. The primary content available is navigational …

Enterprise value to revenue forward of CRISM Therapeutics Corporation – LSE:CRTX

E.W. Scripps Co (SSP) executive discloses RSU and share holdings

Kevin D. Littleton, President, Media of E.W. Scripps Co, has reported his initial beneficial ownership in the company. He directly holds 48,558 Class A Common Shares and also has restricted stock unit awards totaling 224,604 shares which are scheduled to vest between 2027 and …

AMG Critical Materials (ENXTAM:AMG) Stock Looks Near Fair Value After 35% Gain

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AMG Critical Materials stock has returned 35.0% over the past year, and after that …

Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences (NBIX), made a bona fide gift of 2,409 shares of common stock effective August 4, 2026. This transaction was a charitable contribution, not a market sale, and no value was received for the shares. After this …

Criteo (NASDAQ: CRTO) sets cross-border merger into U.S. holding company

Criteo S.A. (NASDAQ: CRTO) is planning a cross-border merger into its wholly-owned U.S. subsidiary, Criteo Holdings, Inc., which will result in a one-for-one share exchange for shareholders. The merger is expected to be effective on January 1, 2027, and is contingent upon shareholder approval, …

Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount

Neurocrine Biosciences (NBIX) is presented as a compelling value stock due to its strong valuation score, profitability, and growth prospects despite trading at a higher-than-average P/E. The company boasts excellent financial health, a debt-free balance sheet, and impressive historical and projected EPS and revenue …

Criteo Sa earnings beat by $0.10, revenue topped estimates

Criteo Sa (NASDAQ: CRTO) reported second-quarter EPS of $0.80, surpassing analyst estimates by $0.10. The company's revenue for the quarter was $428 million, significantly exceeding the consensus estimate of $263.51 million. Despite a 6.55% decrease over the last 12 months, the stock has risen …

Criteo Releases Q2 2026 Financial Results

Criteo S.A. reported strong Q2 2026 financial results, exceeding Wall Street expectations with adjusted earnings of $0.80 per share against an estimated $0.69, and revenue reaching $428.0M compared to a $263.4M consensus. Despite a year-over-year revenue decline, the company demonstrated successful cost management, achieving …

Acrivon advances cancer drug ACR-2316 to dose expansion phase

Acrivon Therapeutics Inc. (NASDAQ:ACRV) has advanced its experimental cancer drug ACR-2316 to the randomized dose expansion phase of its Phase 1/2 study, selecting 120 mg and 160 mg oral doses. This decision follows successful dose escalation in 35 subjects, where the WEE1/PKMYT1 inhibitor showed …

Criteo Q2 Earnings Call Highlights

Key Points Interested in Criteo S.A.? Here are five stocks we like better. Criteo lowered its 2026 outlook after second-quarter results missed expectations, primarily because several large Performance Media clients reduced spending. Full-year Contribution ex-TAC is now expected to decline 10% to 12% at …

Cricut (NASDAQ:CRCT) Sees Unusually-High Trading Volume After Earnings Beat

Crinetics Pharmaceuticals (CRNX) Stock Lags As Revenue Builds And Losses Deepen

Crinetics Pharmaceuticals (CRNX) has shown significant revenue growth, with Q2 2026 revenue reaching US$25.1 million, largely due to scaling product sales like PALSONIFY. Despite this, the company's net losses have deepened, reporting a US$120.9 million quarterly loss and a US$501.6 million trailing 12-month loss. …

Cricut, Inc. (NASDAQ:CRCT) Receives Consensus Rating of "Strong Sell" from Brokerages

Breaking News about Cricut, Inc. - Class A common stock (Nasdaq:CRCT)

This article provides recent news and financial updates concerning Cricut, Inc. (NASDAQ:CRCT), including its Q2 2026 earnings beat, Q1 2026 earnings transcript, and mixed Q4 results with profitability gains. It also lists several scheduled earnings dates and mentions Cricut in various stock analyses and …

Strata Critical Medical (SRTA) Stock Faces Clinical Progress And Lingering Losses

Strata Critical Medical (SRTA) reported Q2 2026 results showing significant clinical revenue growth, reaching US$72.5m, and improved adjusted EBITDA margins, signaling a successful pivot towards clinical services. Despite these operational improvements and positive free cash flow, the company continues to face losses, a short …

CRITEO REPORTS SECOND QUARTER 2026 RESULTS

Criteo S.A. reported disappointing financial results for the second quarter of 2026, with revenue decreasing by 11% and net income by 49% year-over-year. Despite the decline, the company remains confident in its Commerce Intelligence strategy, appointing Connor McGogney as CFO and expanding its Retail …

Should Value Investors Buy Carter's (CRI) Stock?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends …

Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. This follows similar Buy ratings from William Blair, though Morgan Stanley maintained a Hold. The company recently reported Q2 revenue of $10.18 million and …

Acrivon Therapeutics (ACRV) Projected to Post Earnings on Wednesday

Acrivon Reports 3 Lung Cancer Subjects on Treatment for Over a Year

Acrivon Therapeutics announced that its drug candidate, ACR-2316, a WEE1/PKMYT1 inhibitor, has advanced to randomized dose expansion in its Phase 1/2 study. This progression is based on a favorable safety profile and observed clinical activity, including tumor shrinkage and partial responses, with three lung …